Granules India in focus after net profit jumps 39% in quarter to September 2026

what happened

Granules India shares stay on investors' radar on November 3 after the company reported stronger quarterly earnings for the period ended September 2026, TradingView says. Net profit climbed 39.2% year on year to Rs 182 crore, up from Rs 131 crore a year earlier.

Revenue rose 20.3% to Rs 1,560 crore from Rs 1,297 crore. EBITDA grew 21.3% to Rs 337.4 crore from Rs 278.1 crore, and the EBITDA margin widened to 21.6% from 21.4%.

Separately, the US Food and Drug Administration carried out a current Good Manufacturing Practice inspection at the finished dosage facility in Gagillapur, Hyderabad, from October 19 to October 30, 2026. It ended with a Form FDA 483 listing eleven observations. In the previous session the stock closed at Rs 819.55, down Rs 20.00, or 2.38%.

why it matters

For investors, the key signal is margin resilience: profit is growing much faster than revenue, which typically draws attention to a company's stock. The FDA observations, however, could become a risk for production and drug exports if the regulator requires corrective steps.

market impact

Granules India shares: strong results support the stock, FDA observations are a risk to production

• ▲Granules India shares pressure up — faster profit and revenue growth raises interest in the company's stock

tags

instruments